483
Samsung Biologics Co., Ltd.Samsung Biologics Co., Ltd. – FDA 483, Nov 1, 2019
Record Details
An FDA inspection of Samsung Biologics Co. Ltd., a sterile pharmaceutical manufacturer in Incheon, Korea, revealed significant deficiencies in their quality system. The firm failed to properly record and justify deviations from written production and process control procedures. Specifically, "GMP Incidents" were closed without adequate investigation or corrective actions, and the system for identifying reoccurring deviations was found to be insufficient.
View Company Profile
ID · 1d997c69-57a4-460b-a2c0-85acb578f22f
Other documents for Samsung Biologics Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.